AR017722A1 - Una solucion acuosa a base de clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluorometil fenil)-1,2,3,6-tetrahidropiridina (clorhidrato de sr 57746), una composicion farmaceutica bebible, en unidades de dosificacion, que comprende a dicha solucion acuosa y un complejo formado con una molecula de sr 577 - Google Patents
Una solucion acuosa a base de clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluorometil fenil)-1,2,3,6-tetrahidropiridina (clorhidrato de sr 57746), una composicion farmaceutica bebible, en unidades de dosificacion, que comprende a dicha solucion acuosa y un complejo formado con una molecula de sr 577Info
- Publication number
- AR017722A1 AR017722A1 ARP980106588A ARP980106588A AR017722A1 AR 017722 A1 AR017722 A1 AR 017722A1 AR P980106588 A ARP980106588 A AR P980106588A AR P980106588 A ARP980106588 A AR P980106588A AR 017722 A1 AR017722 A1 AR 017722A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrochloride
- amount
- chlorhydrate
- ethyl
- beta
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Abstract
La 1-[2-(2-naftil)etil]-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina(SR 57746)- y sus sales farmacéuticamente aceptables, en especial suclorhidrato, han sido descriptas como agentes anorexígenos y, por lo tanto, como antiansiodepresores,anti constipantes, neurotropicos, antiradicales libres,cardioprotectores y como agentes utiles para el tratamiento de la esclerosis lateral amiotrofica. Sin embargo la baja solubilidad del SR 57746 y de sus salesen agua, en especial el clorhidrato,así co mo la inestabilidad de las soluciones acuosas así formadas, representan un problema serio para la administracion yel almacenamiento de soluciones que contienen dicho compuesto. Este problema se pone de manifiesto de manera aun más importante,cuando se decide preparar unasolucion acuosa bebible que pueda tragarse fácilmente por pacientes que presentan problemas de deglucion. Se revelan una solucion acuosa a base de clorhidratode 1-[2-(2-naftil)etil]-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropi ridina (clorhidrato de SR 57746) que comprende: una cantidad no nula de beta-CD inferioro igual a 50 mg/ml; una cantidad no nula de clorhidrato de SR 57746 (en mg/ml) inferior o igual al décimo de beta-CD expresada en mg/ml; un ácido oun tamponfarma céuticamente aceptable para asegurar un pH inferior o igual a 3; entendiéndose que para una cantidad de beta-CD que va de 30 a 50 mg/ml, la cantidad declorhidrato de SR 57746 verifica la ecuacion: cantidad de clorhidrato de SR 57747(mg/ml) > o = [(c antidad de beta-CD (mg/ml)/10)-3]. Una composicionfarmacéutica bebible, en unidades de dosificacion, que comprende a dicha solucion acuosa y un complejo formado por una molécula de SR 57746.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9716529A FR2772614B1 (fr) | 1997-12-24 | 1997-12-24 | Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017722A1 true AR017722A1 (es) | 2001-09-12 |
Family
ID=9515152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106588A AR017722A1 (es) | 1997-12-24 | 1998-12-22 | Una solucion acuosa a base de clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluorometil fenil)-1,2,3,6-tetrahidropiridina (clorhidrato de sr 57746), una composicion farmaceutica bebible, en unidades de dosificacion, que comprende a dicha solucion acuosa y un complejo formado con una molecula de sr 577 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6191137B1 (es) |
| EP (1) | EP1041984B1 (es) |
| JP (1) | JP2002510599A (es) |
| AR (1) | AR017722A1 (es) |
| AT (1) | ATE252384T1 (es) |
| AU (1) | AU1880599A (es) |
| BR (1) | BR9814414A (es) |
| CA (1) | CA2315696C (es) |
| CO (1) | CO4970813A1 (es) |
| DE (1) | DE69819203T2 (es) |
| DK (1) | DK1041984T3 (es) |
| DZ (1) | DZ2676A1 (es) |
| ES (1) | ES2209238T3 (es) |
| FR (1) | FR2772614B1 (es) |
| GT (1) | GT199800204A (es) |
| HU (1) | HUP0101012A3 (es) |
| MY (1) | MY117156A (es) |
| NO (1) | NO20003284L (es) |
| PT (1) | PT1041984E (es) |
| SA (2) | SA99191003B1 (es) |
| SI (1) | SI1041984T1 (es) |
| TW (1) | TW536409B (es) |
| UY (1) | UY25320A1 (es) |
| WO (1) | WO1999033466A1 (es) |
| ZA (1) | ZA9811824B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070053883A1 (en) * | 2003-03-25 | 2007-03-08 | The Johns Hopkins University | Neuronal cell lineages and methods of production thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2702656B1 (fr) * | 1993-03-18 | 1995-06-16 | Sanofi Elf | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs. |
-
1997
- 1997-12-24 FR FR9716529A patent/FR2772614B1/fr not_active Expired - Fee Related
-
1998
- 1998-12-14 AU AU18805/99A patent/AU1880599A/en not_active Abandoned
- 1998-12-14 SI SI9830580T patent/SI1041984T1/xx unknown
- 1998-12-14 HU HU0101012A patent/HUP0101012A3/hu unknown
- 1998-12-14 WO PCT/FR1998/002712 patent/WO1999033466A1/fr active IP Right Grant
- 1998-12-14 AT AT98963579T patent/ATE252384T1/de not_active IP Right Cessation
- 1998-12-14 EP EP98963579A patent/EP1041984B1/fr not_active Expired - Lifetime
- 1998-12-14 US US09/581,718 patent/US6191137B1/en not_active Expired - Fee Related
- 1998-12-14 CA CA002315696A patent/CA2315696C/en not_active Expired - Fee Related
- 1998-12-14 BR BR9814414-6A patent/BR9814414A/pt not_active Application Discontinuation
- 1998-12-14 DK DK98963579T patent/DK1041984T3/da active
- 1998-12-14 DE DE69819203T patent/DE69819203T2/de not_active Expired - Fee Related
- 1998-12-14 JP JP2000526223A patent/JP2002510599A/ja active Pending
- 1998-12-14 ES ES98963579T patent/ES2209238T3/es not_active Expired - Lifetime
- 1998-12-14 PT PT98963579T patent/PT1041984E/pt unknown
- 1998-12-15 DZ DZ980286A patent/DZ2676A1/xx active
- 1998-12-17 CO CO98075012A patent/CO4970813A1/es unknown
- 1998-12-21 UY UY25320A patent/UY25320A1/es not_active IP Right Cessation
- 1998-12-22 GT GT199800204A patent/GT199800204A/es unknown
- 1998-12-22 AR ARP980106588A patent/AR017722A1/es active IP Right Grant
- 1998-12-23 ZA ZA9811824A patent/ZA9811824B/xx unknown
- 1998-12-23 TW TW087121529A patent/TW536409B/zh not_active IP Right Cessation
- 1998-12-24 MY MYPI98005880A patent/MY117156A/en unknown
-
1999
- 1999-01-26 SA SA99191003A patent/SA99191003B1/ar unknown
- 1999-01-26 SA SA99191002A patent/SA99191002B1/ar unknown
-
2000
- 2000-06-22 NO NO20003284A patent/NO20003284L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9814414A (pt) | 2000-10-10 |
| HUP0101012A3 (en) | 2002-12-28 |
| PT1041984E (pt) | 2004-02-27 |
| JP2002510599A (ja) | 2002-04-09 |
| CA2315696A1 (en) | 1999-07-08 |
| SA99191003B1 (ar) | 2006-10-02 |
| NO20003284L (no) | 2000-08-24 |
| DE69819203T2 (de) | 2004-07-15 |
| UY25320A1 (es) | 2000-10-31 |
| ZA9811824B (en) | 1999-06-29 |
| FR2772614B1 (fr) | 2000-03-10 |
| SI1041984T1 (en) | 2004-04-30 |
| SA99191002B1 (ar) | 2006-03-07 |
| ATE252384T1 (de) | 2003-11-15 |
| DZ2676A1 (fr) | 2004-09-19 |
| MY117156A (en) | 2004-05-31 |
| AU1880599A (en) | 1999-07-19 |
| TW536409B (en) | 2003-06-11 |
| HUP0101012A2 (hu) | 2001-08-28 |
| CO4970813A1 (es) | 2000-11-07 |
| CA2315696C (en) | 2008-01-29 |
| DK1041984T3 (da) | 2004-02-16 |
| ES2209238T3 (es) | 2004-06-16 |
| EP1041984A1 (fr) | 2000-10-11 |
| DE69819203D1 (de) | 2003-11-27 |
| WO1999033466A1 (fr) | 1999-07-08 |
| FR2772614A1 (fr) | 1999-06-25 |
| US6191137B1 (en) | 2001-02-20 |
| EP1041984B1 (fr) | 2003-10-22 |
| NO20003284D0 (no) | 2000-06-22 |
| GT199800204A (es) | 2000-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
| AT500684B8 (de) | Verwendung von schwefelhältigen carbonsäuren zur herstellung eines arzneimittels zur bekämpfung von erkrankungen durch retroviren | |
| KR940008681A (ko) | 디클로페낙 염용 비경구 용액 | |
| NO20003332L (no) | Midisinforløper av aspartylproteaseinhibitorer | |
| GEP20053454B (en) | Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof | |
| JP2002529490A (ja) | 歯牙吸収性病変の阻害方法 | |
| TW200642685A (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| HU220044B (hu) | Dezmopresszin tartalmú stabilizált vizes gyógyászati készítmények | |
| KR890016966A (ko) | 신규 항바이러스제 | |
| RU2005105576A (ru) | Производные плевромутилина в качестве противомикроюных средств | |
| KR970025615A (ko) | 암 전이 억제제 | |
| KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
| AR017722A1 (es) | Una solucion acuosa a base de clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluorometil fenil)-1,2,3,6-tetrahidropiridina (clorhidrato de sr 57746), una composicion farmaceutica bebible, en unidades de dosificacion, que comprende a dicha solucion acuosa y un complejo formado con una molecula de sr 577 | |
| ATE307588T1 (de) | Pharmazeutische formulierung enhaltend midazolam zur buccalen verabreichung | |
| JP4885513B2 (ja) | オキシメタゾリン含有水性組成物 | |
| KR960017663A (ko) | 결합 수용체 길항물질 | |
| HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| JP2006151955A (ja) | 水性組成物 | |
| JP2006131628A (ja) | オキシメタゾリン含有水性組成物 | |
| JP2006131627A (ja) | オキシメタゾリン含有水性組成物 | |
| KR890003378A (ko) | 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물 | |
| JP2006151969A (ja) | ビタミンｂ６類含有水性組成物 | |
| TR199800716T2 (xx) | Trombosit k�melenme inhibit�rleri ihtiva eden farmas�tik terkipler. | |
| JPS62265220A (ja) | １，４−ジヒドロキシ−５，８−ビス〔２−（２−ヒドロキシエチルアミノ）−エチルアミノ〕アントラキノン二塩酸塩の安定な注射用医薬配合物 | |
| JPH10259132A (ja) | 点鼻用水性懸濁液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |